Enhancing preclinical predictivity

IMMUNO-ONCOLOGY INSIGHTS

July 2021

Enhancing preclinical predictivity

Download PDF

Foreword

Enhancing preclinical predictivity: what is going wrong between preclinical in vitro/in vivo and clinical in vivo settings?

Enhancing preclinical predictivity: what is going wrong between preclinical in vitro/in vivo and clinical in vivo settings?

Christian Schmees

Editorial

Microphysiological systems for immuno-oncology: opportunities and challenges

Microphysiological systems for immuno-oncology: opportunities and challenges

Expert Insight

Advancement of precision oncology by integration of highly sensitive protein profiling technologies and patient-derived cell models for functional efficacy testing

Advancement of precision oncology by integration of highly sensitive protein profiling technologies and patient-derived cell models for functional efficacy testing

Michael Pawlak, Markus Templin, Christian Schmees

Expert Roundtable Video

Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?

Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?

P Ellmark, D Gilham, M Steegmaier et al.

Expert Roundtable

Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?

Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?

Interview

Recent evolution in the bispecific antibody and engineered cytokine fields

Recent evolution in the bispecific antibody and engineered cytokine fields

Translational R&D insights for the allogeneic CAR T cell therapy field and beyond

Translational R&D insights for the allogeneic CAR T cell therapy field and beyond